The molecular characterization of ACC to date uncovered the beta-catenin pathway as a potential target for therapies, in particular TP53, APC, CTNNB1, CDKN1C, IGF-2, NF1, RB1, and menin gene alterations as possible targets [8]. Here, TP53 is linked to adrenal cortex carcinoma.